Lactic acid activates the MondoA–TXNIP pathway, dampening CD8⁺ T cell responses and boosting regulatory T cell function. Inhibiting MondoA revives antitumour immunity and amplifies the effects of anti-PD-1 treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Peralta, R. M. et al. Nat. Immunol. 25, 2297–2307 (2024).
Qiu, Y. et al. Trends Endocrinol. Metab. 35, 967–980 (2024).
Liu, Y. et al. Sci. Transl. Med. 16, eadk7399 (2024).
Ma, J. et al. Nat. Immunol. 25, 552–561 (2024).
Wang, Z. et al. Cell Rep. 43, 113796 (2024).
Feng, Q. et al. Nat. Commun. 13, 4981 (2022).
Cheng, H. et al. Nat. Metab. 5, 314–330 (2023).
Zhang, Y. T. et al. Mol. Immunol. 154, 96–107 (2023).
Watson, M. J. et al. Nature 591, 645–651 (2021).
Ding, R. et al. Immunity 57, 528–540.e6 (2024).
Su, J. et al. Oncoimmunology 13, 2320951 (2024).
Xu, N. et al. Nat. Metab. https://doi.org/10.1038/s42255-025-01347-1 (2025).
Ahn, B. et al. J. Clin. Invest. 126, 3567–3579 (2016).
Lu, Y. et al. Gastroenterology 161, 575–591.e16 (2021).
Acknowledgements
This work was supported by the National Natural Science Foundation of China (32270994 to G.L.), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2021-RC310-014 and 2024-JKCS-15 to G.L.), the CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-1-047, 2021-I2M-1-061, 2022-I2M-2-004, 2023-I2M-QJ-019, 2023-I2M-2-010 and 2024-I2M-ZD-009 to G.L.), the Gusu Innovation and Entrepreneurship Talent Program (ZXL2022503 to G.L.) and the Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0520600 to G.L.). We thank the Suzhou Municipal Key Laboratory (SZS2023005) and the NCTIB Fund for R&D Platform for Cell and Gene Therapy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Xie, E., Li, G. Dual gains from targeting MondoA in T cells. Nat Metab 7, 1725–1727 (2025). https://doi.org/10.1038/s42255-025-01329-3
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s42255-025-01329-3
